David Messenheimer is a highly accomplished translational research scientist with an impressive academic and pharmaceutical background that spans over nine years. He has a keen interest in the interaction between cancer and the immune system and focuses on generating and harnessing an immune response to eliminate tumors and improve patients' lives. David possesses a strong background in preclinical tumor models, T cell activation assays, flow cytometry, optimization of combination treatments with tumor vaccines, and combinations of checkpoint antibodies targeting costimulatory/inhibitory receptors. His excellent written and oral communication skills have been showcased in his presentations at major international meetings. David has held various positions, including Senior Scientist at Boehringer Ingelheim, Postdoctoral Researcher at the Earle A. Chiles Research Institute, Graduate Student Intern at Earle A. Chiles Research Institute, and Research Associate II at Colorado State University. Additionally, he has had experience as a Board of Director member at USA Triathlon and as a Professional Athlete at USA Triathlon, showcasing his diverse background.